Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04761536
Other study ID # REGISTROSPERIMENTAZIONI XX/21
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 2006
Est. completion date January 31, 2021

Study information

Verified date February 2021
Source University of Rome Tor Vergata
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Hospital centralization effect is reported to lower complications and mortality especially for high risk and complex general surgery operations, including colorectal surgery. However, no linear relation between volume and outcome has been demonstrated. Aim of the study was to evaluate the increased surgical volume effect on early outcomes of patient undergoing restorative anterior rectal resection (ARR).


Recruitment information / eligibility

Status Completed
Enrollment 187
Est. completion date January 31, 2021
Est. primary completion date December 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - diagnosis of a cancer located in the rectum, defined according to the international definition by D'Souza et al., - elective setting - anterior rectal resection with primary anastomosis (with or without diverting loop ileostomy). Exclusion Criteria: - age below age of 18, - inflammatory bowel disease, - acquired or congenital immunodeficiency, - preoperative infection, - pregnancy, - ASA IV, - presence of synchronous cancers, - abdominoperineal resection (APR), - failure to perform rectal resection and primary anastomosis, - emergency setting.

Study Design


Intervention

Other:
Rectal cancer case centralization
In November 2016, the decision to centralize rectal cancer patients to only one surgical unit was taken, with only two surgeons performing the procedures. Furthermore, a close collaboration with local Gastroenterology Units and General Practiotioners was started in order to increase colorectal cancer case referral to our unit. At the same time, we decided to promote the use of laparoscopy and to implement ERAS protocol in our colorectal surgery practice.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Rome Tor Vergata

Outcome

Type Measure Description Time frame Safety issue
Primary Anastomotic leak rate of any postoperative leakage of colo-rectal anastomosis clinically, radiologically or endoscopically demonstrated up to 30 days after discharge
Secondary Postoperative complications rate of any surgical site infection clinically demonstrated up to 30 days after discharge
Secondary Surgical site infection Rate of any complication after rectal resection up to 30 days after discharge
Secondary Pneumonia rate of radiologically demonstrated pneumonia up to 30 days after discharge
Secondary Ileus rate of any ileus clinically demonstrated up to 30 days after discharge
Secondary Bleeding Rate of any clinically radiologically or endoscopically demonstrated bleeding after rectal resection up to 30 days after discharge
Secondary Reoperation Rate of any reoperation up to 30 days after discharge
Secondary Readmission Rate of any unplanned readmission after discharge up to 90 days after discharge
Secondary 30-days-mortality Rate of any mortality up to 30 days after discharge
Secondary 1-year stoma persistence rate of stoma persistence up to one year after surgery
Secondary Length of hospital stay number of days between primary rectal resection and discharge up to 30 days after discharge
Secondary Use of minimally invasive approach rate of minimally invasive rectal ARR performed up to 30 days after discharge
Secondary Operative time Mean operative time up to 30 days after discharge
Secondary Conversion to open surgery rate of conversion form laparoscopy to one surgery up to 30 days after discharge
Secondary need of postoperative blood transfusion rate of postoperative transfusion up to 30 days after discharge
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1